Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | RORC | P51449 | 3/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309433 | 1.00 | KDM4E (0.61) | KDM4ENR4A2LMNARORCCHRM1 | |
| SCHEMBL4079943 | 0.90 | LMNA (0.55) | KDM4ENR4A2LMNARORCCHRM1 | |
| SCHEMBL30309505 | 0.90 | LMNA (0.66) | KDM4ENR4A2LMNARORCCHRM1 | |
| SCHEMBL29004492 | 0.90 | KDM4E (0.54) | KDM4ENR4A2LMNARORCCHRM1 | |
| SCHEMBL30309418 | 0.90 | KDM4E (0.54) | KDM4ENR4A2LMNARORCCHRM1 | |
| SCHEMBL30309390 | 0.90 | LMNA (0.55) | KDM4ENR4A2LMNARORCCHRM1 | |
| SCHEMBL10445864 | 0.90 | LMNA (0.66) | KDM4ENR4A2LMNARORCCHRM1 | |
| SCHEMBL31601057 | 0.88 | NR4A2 (0.69) | KDM4ENR4A2LMNARORCCYP1A2 | |
| SCHEMBL11553625 | 0.88 | NR4A2 (0.69) | KDM4ENR4A2LMNARORCCYP1A2 | |
| SCHEMBL16285135 | 0.87 | NR4A2 (0.56) | KDM4ENR4A2LMNARORCCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115784987-A | Compound related to pneumonia, preparation method and application thereof, and pharmaceutical composition | 国科温州研究院(温州生物材料与工程研究所) | 2023-03-14 | — | — | CN | claimed |
| CN-110642837-B | Pyridine amide compound containing triazole or quinolinone structure and application thereof | 江西科技师范大学 | 2023-03-21 | — | — | CN | disclosed |
| CN-115784987-A | Compound related to pneumonia, preparation method and application thereof, and pharmaceutical composition | 国科温州研究院(温州生物材料与工程研究所) | 2023-03-14 | — | — | CN | disclosed |
| CN-110642837-A | Pyridine amide compound containing triazole or quinolinone structure and application thereof | 江西科技师范大学 | 2020-01-03 | — | — | CN | disclosed |
| US-9382232-B2 | Quinoline and cinnoline derivatives and their applications | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2016-07-05 | — | — | US | disclosed |
| US-20140364431-A1 | Quinoline and cinnoline derivatives and their applications | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2014-12-11 | — | — | US | disclosed |
| US-7339061-B2 | 3-(4-oxo-4H-chromen-2-yl)-(1H)-quinolin-4-one derivatives, method for preparing same and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2008-03-04 | — | — | US | disclosed |
| EP-1513833-B1 | NOVEL 3-(4-OXO-4H-CHROMEN-2-YL)-(1H)-QUINOLINE-4-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2006-04-19 | — | — | EP | disclosed |
| US-20060063801-A1 | Novel 3-(4-oxo-4h-chromen-2-yl)-(1H)-quinolin-4-one derivatives, method for preparing same and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2006-03-23 | — | — | US | disclosed |
| CN-1692110-A | New 3-(4-oxygen-4H-benzopyranyl-2-base)-(1H)-quinoline-4-ketone derivant, its preparing method and drug compositions containing them | SERVIER LAB (FR) | 2005-11-02 | — | — | CN | disclosed |
| EP-1513833-A1 | NOVEL 3-(4-OXO-4H-CHROMEN-2-YL)-(1H)-QUINOLINE-4-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier (FR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000834-A1 | NOVEL 3-(4-OXO-4H-CHROMEN-2-YL)-(1H)-QUINOLINE-4-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2003-12-31 | — | — | WO | disclosed |
| US-5225419-A | Antagonist 5-hydroxytryptamine for treatment of nausea or vomiting | JOHN WYETH & BROTHER, LIMITED (GB) | 1993-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364431-A1 | Quinoline and cinnoline derivatives and their applications | MET, CHEK1, KIT | KDM4E 2948/4885NR4A2 3851/4885LMNA 1240/4885 |
| US-20060063801-A1 | Novel 3-(4-oxo-4h-chromen-2-yl)-(1H)-quinolin-4-one derivatives, method for preparing same and pharmaceutical compositions containing same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, RB1 | KDM4E 2379/4885NR4A2 671/4885LMNA 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.